Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: A randomized double-blinded crossover study

Diabetic Medicine

Volumn 22, Issue 3, 2005, Pages 273-277

  Chen, Jian Wen ^a,b   Lauritzen, T ^b   Christiansen, J J ^a   Jensen, L H ^c   Clausen, W H O ^c   Christiansen, J S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Biphasic insulin aspart; Pharmacokinetics; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; NOVOMIX 70;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; TIME FACTORS;

EID: 14644421553     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01404.x     Document Type: Article

References (27)

1. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988; 333: 679-682.
2. Brange J. The new era of biotech insulin analogues. Diabetologia 1997; 40: S48-S53.
3. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
4. Kaku K, Matsuda M, Urae A, Irie S. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract 2000; 49: 119-126.
5. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000; 159: 483-488.
6. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21: 1910-1914.
7. Rave K, Heise T, Weyer C, Herrnberger J, Bender R, Hirschberger S et al. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects. Diabet Med 1998; 15: 747-751.
8. ter Braak EW, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JH et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437-1440.
9. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904-1909.
10. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22: 801-805.
11. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-588.
12. Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997; 20: 1287-1289.
13. Hermansen K, Vaaler S, Madsbad S, Dalgaard M, Zander M, Begtrup K et al. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. Metabolism 2002; 51: 896-900.
14. Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399-403.
15. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612-1614.
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998; 21: s5-s19.
17. Andersen L, Jorgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem 2000; 33: 627-633.
18. Rang HP, Dale MM, Ritter JM. Drug elimination and pharmacokinetics. In: Rang, HP, Dale, MM, Ritter, JM, eds. Textbook of Pharmacology, 4th edn. London: Churchill Livingstone, 1999; 5: 78-92.
19. Linde B. The pharmacokinetics of insulin. In: Pickup, JC, Williams, G, eds. Textbook of Diabetes, 2nd edn. Oxford: Blackwell Science, 1997; 32: 1-14.
20. Goeders LA, Esposito LA, Peterson ME. Absorption kinetics of regular and isophane (NPH) insulin in the normal dog. Domest Anim Endocrinol 1987; 4: 43-50.
21. Wallace MS, Peterson ME, Nichols CE. Absorption kinetics of regular, isophane, and protamine zinc insulin in normal cats. Domest Anim Endocrinol 1990; 7: 509-515.
22. Nosadini R, De Kreutzenberg S, Duner E, Iori E, Avogaro A, Trevisan R et al. Porcine and human insulin absorption from subcutaneous tissues in normal and insulin-dependent diabetic subjects: a deconvolution-based approach. J Clin Endocrinol Metab 1988; 67: 551-559.
23. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981; 4: 366-376.
24. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800-803.
25. Woodworth JR, Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Compton J et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care 1994; 17: 366-371.
26. Ahmed AB, Mallias J, Home PD. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. Diabetes Care 1998; 21: 1162-1166.
27. Janssen MM, Snoek FJ, Masurel N, Hoogma RP, Deville WL, Popp-Snijders C et al. Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction. Diabetes Care 2000; 23: 629-633.